|
Catalyst Pharmaceuticals, Inc. (CPRX) DCF Valoración
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Catalyst Pharmaceuticals, Inc. (CPRX) Bundle
¡Simplifique la valoración de Catalyst Pharmaceuticals, Inc. (CPRX) con esta calculadora DCF personalizable! Con Real Catalyst Pharmaceuticals, Inc. (CPRX) financieros y entradas de pronóstico ajustables, puede probar escenarios y descubrir Catalyst Pharmaceuticals, Inc. (CPRX) valor razonable en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.3 | 119.1 | 140.8 | 214.2 | 398.2 | 570.1 | 816.2 | 1,168.5 | 1,672.8 | 2,394.9 |
| Revenue Growth, % | 0 | 16.39 | 18.27 | 52.1 | 85.9 | 43.17 | 43.17 | 43.17 | 43.17 | 43.17 |
| EBITDA | 31.8 | 41.3 | 52.4 | 101.8 | 119.7 | 205.9 | 294.8 | 422.0 | 604.2 | 865.0 |
| EBITDA, % | 31.11 | 34.69 | 37.2 | 47.54 | 30.06 | 36.12 | 36.12 | 36.12 | 36.12 | 36.12 |
| Depreciation | .3 | .9 | .5 | 1.5 | 32.9 | 11.8 | 16.9 | 24.1 | 34.6 | 49.5 |
| Depreciation, % | 0.29101 | 0.74351 | 0.34367 | 0.69373 | 8.26 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 |
| EBIT | 31.5 | 40.4 | 51.9 | 100.4 | 86.8 | 194.1 | 277.9 | 397.9 | 569.6 | 815.5 |
| EBIT, % | 30.81 | 33.94 | 36.85 | 46.85 | 21.8 | 34.05 | 34.05 | 34.05 | 34.05 | 34.05 |
| Total Cash | 94.5 | 140.3 | 191.3 | 298.4 | 137.6 | 486.8 | 696.9 | 997.8 | 1,428.4 | 2,045.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 10.5 | 6.0 | 6.6 | 10.4 | 53.5 | 43.7 | 62.6 | 89.6 | 128.3 | 183.6 |
| Account Receivables, % | 10.3 | 5.03 | 4.7 | 4.87 | 13.44 | 7.67 | 7.67 | 7.67 | 7.67 | 7.67 |
| Inventories | 2.0 | 4.7 | 7.9 | 6.8 | 15.6 | 21.1 | 30.2 | 43.3 | 61.9 | 88.7 |
| Inventories, % | 1.91 | 3.91 | 5.59 | 3.18 | 3.93 | 3.7 | 3.7 | 3.7 | 3.7 | 3.7 |
| Accounts Payable | 4.1 | 4.3 | 2.8 | 4.0 | 14.8 | 17.3 | 24.7 | 35.4 | 50.6 | 72.5 |
| Accounts Payable, % | 4.02 | 3.57 | 1.97 | 1.86 | 3.72 | 3.03 | 3.03 | 3.03 | 3.03 | 3.03 |
| Capital Expenditure | .0 | .0 | -1.0 | .0 | -198.5 | -57.7 | -82.6 | -118.3 | -169.4 | -242.5 |
| Capital Expenditure, % | -0.01893236 | -0.0095723 | -0.72497 | -0.01353856 | -49.85 | -10.12 | -10.12 | -10.12 | -10.12 | -10.12 |
| Tax Rate, % | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 |
| EBITAT | 30.1 | 72.3 | 38.9 | 79.6 | 65.6 | 165.1 | 236.4 | 338.4 | 484.5 | 693.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 22.0 | 75.2 | 33.0 | 79.5 | -141.1 | 126.0 | 150.1 | 214.9 | 307.6 | 440.4 |
| WACC, % | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 941.5 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 454 | |||||||||
| Terminal Value | 9,059 | |||||||||
| Present Terminal Value | 6,163 | |||||||||
| Enterprise Value | 7,104 | |||||||||
| Net Debt | -134 | |||||||||
| Equity Value | 7,239 | |||||||||
| Diluted Shares Outstanding, MM | 114 | |||||||||
| Equity Value Per Share | 63.63 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to generate various scenarios.
- Real-World Data: Catalyst Pharmaceuticals, Inc.’s (CPRX) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and saving time.
Key Features
- Comprehensive CPRX Data: Pre-filled with Catalyst Pharmaceuticals' historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
- User-Friendly Interface: Intuitive, organized, and suitable for both professionals and newcomers.
How It Works
- Download: Obtain the pre-built Excel file featuring Catalyst Pharmaceuticals, Inc.'s (CPRX) financial data.
- Customize: Modify forecasts, including revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: Real-time updates for intrinsic value and NPV calculations as you make changes.
- Test Scenarios: Develop various projections and instantly compare the results.
- Make Decisions: Leverage the valuation findings to inform your investment strategy.
Why Choose This Calculator for Catalyst Pharmaceuticals, Inc. (CPRX)?
- Accuracy: Utilizes real Catalyst Pharmaceuticals financial data for precise calculations.
- Flexibility: Allows users to easily test and adjust inputs to fit their needs.
- Time-Saving: Avoid the complexities of constructing a DCF model from the ground up.
- Professional-Grade: Crafted with the precision and usability expected by CFOs.
- User-Friendly: Designed for ease of use, suitable for individuals without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Accurately assess Catalyst Pharmaceuticals’ fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis related to Catalyst Pharmaceuticals (CPRX).
- Consultants: Easily customize the template for valuation reports for clients in the pharmaceutical sector.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading pharmaceutical companies.
- Educators: Employ it as a teaching resource to illustrate valuation methodologies in the biotech industry.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Catalyst Pharmaceuticals, Inc. (CPRX).
- Real-World Data: Catalyst Pharmaceuticals' historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Catalyst Pharmaceuticals.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results related to Catalyst Pharmaceuticals, Inc. (CPRX).